You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

exon 13

Showing 1 - 25 of 3,180
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Dallas, Madison, London (QR-421a, Sham-procedure)

Active, not recruiting
  • Retinitis Pigmentosa
  • +7 more
  • Dallas, Texas
  • +2 more
Apr 21, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose

Completed
  • Retinitis Pigmentosa
  • +7 more
  • QR-421a
  • Sham-procedure (dose cohort 1&2 only)
  • Boston, Massachusetts
  • +6 more
Apr 19, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

Recruiting
  • Retinitis Pigmentosa
  • +7 more
  • San Diego, California
  • +14 more
Jul 29, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2 Trial in Canada, France, United States (RNA antisense oligonucleotide for

Terminated
Has Results
  • Retinitis Pigmentosa
  • Usher Syndrome Type 2
  • RNA antisense oligonucleotide for intravitreal injection
  • Boston, Massachusetts
  • +6 more
Dec 12, 2022

Gastrointestinal Stromal Tumors Trial in Miami (Sunitinib, Regorafenib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Miami, Florida
    University of Miami
Jan 3, 2023

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

Duchenne Muscular Dystrophy Trial (NS-050/NCNP-03, Placebo)

Not yet recruiting
  • Duchenne Muscular Dystrophy
  • (no location specified)
Sep 19, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

Osimertinib for NSCLC With Uncommon EGFR Mutations

Enrolling by invitation
  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1
  • Ramat Gan, Israel
    Sheba Medical Centre
Jun 14, 2022

Non-small Cell Lung Cancer EGFR Exon 20 Insertion

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • Cordoba, Andalucia, Spain
    • +14 more
    Nov 1, 2022

    Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

    Not yet recruiting
    • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    • Bengbu, Anhui, China
    • +51 more
    Mar 11, 2023

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Avapritinib in Chinese Gastrointestinal Stromal Tumor in Real

    Recruiting
    • Gastrointestinal Stromal Tumors
    • Avapritinib
    • Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 14, 2022

    Duchenne Muscular Dystrophy Trial in Portland (NS-089/NCNP-02)

    Not yet recruiting
    • Duchenne Muscular Dystrophy
    • Portland, Oregon
      Shriners Hospital for Children
    Aug 16, 2023

    Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial (Poziotinib

    Not yet recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +3 more
    • Poziotinib Hydrochloride
    • 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
    • (no location specified)
    Jul 18, 2022

    NSCLC Trial in Worldwide (Afatinib)

    Completed
    Has Results
    • NSCLC
    • Köln, Germany
    • +4 more
    Aug 23, 2022

    Mobocertinib in Adults With Lung Cancer in China (MEANING)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Shanghai, China
      Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai J
    May 9, 2023

    Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

    Completed
    Has Results
    • Malignant Non-small Cell Neoplasm of Lung Stage IV
    • Capmatinib (INC280)
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 11, 2022

    Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations

    Not yet recruiting
    • Gastrointestinal Stromal Tumors
    • +2 more
      • (no location specified)
      Jul 15, 2022

      Locally Advanced or Metastatic NSCLC Trial in Worldwide (Trastuzumab Deruxtecan, Cisplatin, Carboplatin)

      Recruiting
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • Trastuzumab Deruxtecan
      • +4 more
      • Anchorage, Alaska
      • +148 more
      Aug 11, 2022

      GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

      Recruiting
      • Gastro-intestinal Stromal Tumor
      • Vena puncture for blood collection
      • Tumor biopsy
      • Amsterdam, Netherlands
      • +4 more
      May 17, 2022

      Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

      Not yet recruiting
      • Advanced Cancer
      • Non Small Cell Lung Cancer
      • (no location specified)
      Mar 28, 2023

      GIST Trial (Ripretinib, Sunitinib)

      Not yet recruiting
      • GIST
      • (no location specified)
      Feb 8, 2023

      Androgen Receptor Polymorphism on Endometrial Cancer

      Not yet recruiting
      • Androgen Receptor Abnormal
      • Endometrial Disorder
      • Endometrial sampling and Peripheral blood collection
      • FSFI Scale
      • (no location specified)
      Dec 12, 2021

      NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • MK-2870
      • +2 more
      • (no location specified)
      Oct 3, 2023